1-11 of 11
Xiaoling Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6500: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor

Xiaoling Zhang, Elaine Liu, Yan Song, Peony Yu, Sanjeev Redkar, Guo-Liang Yu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6500.
https://doi.org/10.1158/1538-7445.AM2024-6500
Published: 22 March 2024
View articletitled, Abstract 6500: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor
Journal Articles

Abstract 597: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels

Xiaoling Zhang, Elaine Liu, Yan Song, Peony Yu, Sanjeev Redkar, Guo-Liang Yu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 597.
https://doi.org/10.1158/1538-7445.AM2024-597
Published: 22 March 2024
View articletitled, Abstract 597: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels
Journal Articles

Abstract P5-09-05: A phase II, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

zhen shan, nan shao, xiaoling zhang, huijuan shi, yanling zheng, jia luo, tiantian zhen, ruping chen, Ying Lin
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-09-05.
https://doi.org/10.1158/1538-7445.SABCS22-P5-09-05
Published: 01 March 2023
View articletitled, Abstract P5-09-05: A phase II, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)
Journal Articles

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

Jessica Koach, Jessica K. Holien, Hassina Massudi, Daniel R. Carter, Olivia C. Ciampa, Mika Herath, Taylor Lim, Janith A. Seneviratne, Giorgio Milazzo, Jayne E. Murray, Joshua A. McCarroll, Bing Liu, Chelsea Mayoh, Bryce Keenan, Brendan W. Stevenson, Michael A. Gorman, Jessica L. Bell, Larissa Doughty, Stefan Hüttelmaier, Andre Oberthuer, Matthias Fischer, Andrew J. Gifford, Tao Liu, Xiaoling Zhang, Shizhen Zhu, W. Clay Gustafson, Michelle Haber, Murray D. Norris, Jamie I. Fletcher, Giovanni Perini, Michael W. Parker, Belamy B. Cheung, Glenn M. Marshall
Journal: Cancer Research
Series: Author Choice
Cancer Res (2019) 79 (21): 5652–5667.
https://doi.org/10.1158/0008-5472.CAN-19-1112
Published: 01 November 2019
View articletitled, Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Open the PDF for Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface in another window
Includes: Supplementary data
Journal Articles

Abstract 2205: CBT-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering means of controlling tumor associated macrophages

Elaine Liu, Lan Yang, Gavin Choy, Xiaoling Zhang, Tillman Pearce, Mamatha Reddy, Sanjeev Redkar, Qian Shi
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2205.
https://doi.org/10.1158/1538-7445.AM2019-2205
Published: 01 July 2019
View articletitled, Abstract 2205: CBT-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering means of controlling tumor associated macrophages
Journal Articles

Abstract IA19: MYC activation through enhancer hijacking or focal enhancer amplification drives a subset of high-risk pediatric neuroblastoma

Mark W. Zimmerman, Yu Liu, Shuning He, Adam D. Durbin, Brian J. Abraham, John Easton, Ying Shao, Beisi Xu, Shizhen Zhu, Xiaoling Zhang, Nina Weichert-Leahey, Richard A. Young, Jinghui Zhang, A. Thomas Look
Journal: Cancer Research
Cancer Res (2018) 78 (19_Supplement): IA19.
https://doi.org/10.1158/1538-7445.PEDCA17-IA19
Published: 01 October 2018
View articletitled, Abstract IA19: MYC activation through enhancer hijacking or focal enhancer amplification drives a subset of high-risk pediatric neuroblastoma
Journal Articles

Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer

Christiaan N. Klijn, Ivana Yen, Frances Shanahan, Mark Merchant, Christine Orr, Thomas Hunsaker, Matthew Durk, Hank La, Xiaoling Zhang, Scott Martin, Eva Lin, John Chan, Yihong Yu, Dhara Amin, Amy Gustafson, Scott Foster, Joachim Rudolph, Shiva Malek
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 874.
https://doi.org/10.1158/1538-7445.AM2018-874
Published: 01 July 2018
View articletitled, Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer
Journal Articles

Abstract 4135: c-MYC drives a subset of high-risk pediatric neuroblastoma and is activated through mechanisms including enhancer hijacking and focal enhancer amplification

Mark W. Zimmerman, Yu Liu, Shuning He, Adam D. Durbin, Brian J. Abraham, John Easton, Ying Shao, Xu Beisi, Shizhen Zhu, Xiaoling Zhang, Zhaodong Li, Nina Weichert-Leahey, Richard A. Young, Jinghui Zhang, A. Thomas Look
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4135.
https://doi.org/10.1158/1538-7445.AM2018-4135
Published: 01 July 2018
View articletitled, Abstract 4135: c-MYC drives a subset of high-risk pediatric neuroblastoma and is activated through mechanisms including enhancer hijacking and focal enhancer amplification
Journal Articles

Abstract 80: Activated SHP2 collaborates with MYCN in neuroblastoma tumorigenesis

Xiaoling Zhang, Guang Yang, A.Thomas Look, Benjamin G. Neel, Shizhen (Jane) Zhu
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 80.
https://doi.org/10.1158/1538-7445.AM2014-80
Published: 01 October 2014
View articletitled, Abstract 80: Activated SHP2 collaborates with MYCN in neuroblastoma tumorigenesis
Journal Articles

Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells

Xiaoling Zhang, Lubing Gu, Jiansha Li, Noopur Shah, Jing He, Lin Yang, Qun Hu, Muxiang Zhou
Journal: Cancer Research
Cancer Res (2010) 70 (23): 9895–9904.
https://doi.org/10.1158/0008-5472.CAN-10-1546
Published: 06 December 2010
View articletitled, Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells
Open the PDF for Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Albumin Adducts of Benzene Oxide and 1,4-Benzoquinone as Measures of Human Benzene Metabolism

Stephen M. Rappaport, Suramya Waidyanatha, Qingshan Qu, Roy Shore, Ximei Jin, Beverly Cohen, Lung-Chi Chen, Assieh A. Melikian, Guilan Li, Songnian Yin, Huifang Yan, Bohong Xu, Ruidong Mu, Yuying Li, Xiaoling Zhang, Keqi Li
Journal: Cancer Research
Cancer Res (2002) 62 (5): 1330–1337.
Published: 01 March 2002
View articletitled, Albumin Adducts of Benzene Oxide and 1,4-Benzoquinone as Measures of Human Benzene Metabolism
Open the PDF for Albumin Adducts of Benzene Oxide and 1,4-Benzoquinone as Measures of Human Benzene Metabolism in another window